Recent Updates — MGRX

Mangoceuticals closed a registered direct offering on October 9, 2026, issuing 657,000 shares of common stock alongside 657,000 common warrants. The securities were sold at $0.75 per unit, generating approximately $492,750 in gross proceeds. Each warrant allows investors to purchase one additional share at an exercise price of $1.00 and expires five years from issuance. Proceeds will support working capital and general corporate purposes.

Mangoceuticals, Inc. announced on September 30, 2026, that its subsidiary MangoRx IP Holdings secured a $2.5 million strategic investment for a 25% ownership stake in the entity holding the patent portfolio for MGX-0024 antiviral technology. Two accredited investors contributed an initial tranche of $1.75 million, receiving 18.9% (17.5% post-transaction) of MangoRx IP, with a final payment of $750,000 due by November 28, 2026, for the remaining 7.5%. The transaction was structured at the subsidiary level to avoid diluting Mangoceuticals' public common stock. This capital supports commercialization efforts for oral-care and livestock applications under brands like MangoRx and PeachesRx in the telemedicine and health products industry.

Mangoceuticals, Inc. mutually terminated its Business Combination Agreement with Nuclea Energy Inc. on August 19, 2026. The termination occurred because the parties failed to finalize PIPE financing documentation and deposit at least $15 million into escrow by the August 21, 2026 outside date. Each party bears its own costs, and mutual releases of claims were exchanged except for willful breaches. Mangoceuticals operates in the cannabis and wellness industry.

Mangoceuticals, Inc. entered into a Business Combination Agreement with Nuclea Energy Inc. to acquire the developer of the Morpheus lead-cooled microreactor. Former Nuclea shareholders will hold approximately 96% of the combined entity's equity on a fully diluted basis, while existing Mango stockholders will retain about 4%. The transaction includes a minimum $15 million PIPE financing and is subject to stockholder and Nasdaq approvals. Upon closing, Jacob D. Cohen will resign as CEO and become President, Josef Freundorfer will assume the role of CEO, and Sagar Sanghera will join the board as Executive Chairman. Mangoceuticals operates in the men's health and wellness sector via its MangoRx telemedicine platform.

Mangoceuticals, Inc. entered into a Subscription Agreement on June 29, 2026, with an accredited investor for the private placement of 850,000 shares of restricted common stock. The investor paid $0.32 per share, totaling $272,000 in gross proceeds. The agreement includes piggyback registration rights for one year following the subscription date. Mangoceuticals, Inc. is a pharmaceutical company.